Imagion Biosystems has released its Annual Report to Shareholders for the year ended 31 December 2019.
Read the Annual Report.
Home » Annual Report to Shareholders
Imagion Biosystems has released its Annual Report to Shareholders for the year ended 31 December 2019.
Read the Annual Report.
Highlights Blinded review by panel of expert breast radiologists corroborates potential for MagSense® nanoparticle technology to detect tumour cells in lymph nodes by Magnetic Resonance
Highlights: Imagion presented results from MagSense® HER2 Phase I study at global breast cancer meeting showing safety and detectability Tasks expert panel of radiologists with
Imaging agent aids in resolving nodal status MELBOURNE — Imagion Biosystems Limited (ASX: IBX), a company dedicated to improving healthcare through the earlier detection of
We’re on a mission to make cancer more detectable.
Stay informed about our latest news and developments.
© Imagion Biosystems, Ltd. All Rights Reserved | Privacy Policy | Terms & Conditions | Careers | Corporate Governance